We are Anchiano Therapeutics, a pivotal-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of novel targeted therapies to treat cancer.
Our pivotal-stage clinical program is gene therapy for early stage bladder cancer. Inodiftagene vixteplasmid (formerly BC-819) is under development as a treatment for non-muscle-invasive bladder cancer (NMIBC). Inodiftagene has been tested in six clinical trials to date, three of which are in NMIBC. The pivotal development program comprises two registrational trials in NMIBC. The first of these, the Codex Trial, opened in December of 2018 and is recruiting patients now. For more information, click here or visit ClinicalTrials.gov (Identifier: NCT03719300).
We have a partnership with ADT Pharmaceuticals around two small molecule development programs targeting oncogenic pathways, focused on RAS and PDE10/ß-catenin, respectively.
We are located in Cambridge, Massachusetts, and in Jerusalem, Israel and are publicly traded on the Nasdaq (NASDAQ: ANCN).